Abstracts tagged "Infection"

Abstract Number: 0627 • ACR Convergence 2020
Complications of COVID-19 Infection in Patients with Rheumatic Disease: A Case Series
Timothy Buckey¹, Mali Jurkowski¹, Kevin Lu², Roberto Caricchio² and Aruni Jayatilleke², ¹Temple University, Philadelphia, PA, ²Section of Rheumatology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA
Background/Purpose: People with rheumatic diseases may be at high risk for poor outcomes related to COVID-19; on the other hand, immunomodulatory medications are used as…
Abstract Number: 1165 • ACR Convergence 2020
Validation of Healthcare Claims Algorithms for Identification of Herpes Zoster Among Children with Autoimmune/Autoinflammatory Disease
Beth Rutstein¹, Sabrina Gmuca², Jeffrey S. Gerber² and Alexis Ogdie³, ¹The Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Herpes zoster (HZ) is a known serious infectious complication in children with autoimmune/autoinflammatory disease and potentially exacerbated by immunomodulatory medications. Information on HZ burden…
Abstract Number: 0082 • ACR Convergence 2020
Diffuse Sclerosing Osteomyelitis of the Jaw: An Underdiagnosed Disease in Maxillofacial Surgery Department
Pauline Preuss¹, Hélios Bertin¹, Pierre Corre¹ and Benoit Le Goff², ¹Nantes University Hospital, Nantes, France, ²Nantes University Hospital, Nantes, Pays de la Loire, France
Background/Purpose: Diffuse sclerosing osteomyelitis of the jaw is a rare and under-recognized disease. Many authors include this diagnosis in the spectrum of aseptic osteitis sometimes…
Abstract Number: 0628 • ACR Convergence 2020
Factors Associated with Knee Osteoarthritis in an Outpatient HIV-1 Clinic over a 26 Year Interval
Benjamin Naovarat¹, Francis Williams¹, Jonathan Dau², Marka Lyons³, Binh Nguyen⁴, Gloria Salazar³ and John Reveille⁵, ¹The University of Texas McGovern Medical School, Houston, TX, ²Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³University of Texas Houston, McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ⁴The University of Texas-McGovern Medical School, Houston, TX, ⁵Department of Internal Medicine, University of Texas, Houston, TX
Background/Purpose: With the advent of combined antiretroviral therapy (cART), patients with HIV-1 began living longer and started to develop diseases associated with aging such as…
Abstract Number: 1277 • ACR Convergence 2020
Low Cost Composite Markers to Differentiate Infection from Disease Activity in a Febrile Patient with Systemic Lupus Erythematosus
Pankti Mehta¹, Komal Singh¹, Amita Aggarwal¹ and Seema Sharma¹, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
Background/Purpose: Patients with Systemic Lupus Erythematosus (SLE) are at an increased risk of infection owing to immunosuppressive therapy along with coexistent immune dysregulation. It is…
Abstract Number: 008 • 2020 Pediatric Rheumatology Symposium
Incidence and Risk Factors of Hypogammaglobulinemia and Infectious Complications Associated with Rituximab Use in Pediatric Rheumatic Diseases
Mei-Sing Ong¹, Deborah Rothman ² and Marc Natter ³, ¹Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, ²Massachusetts General Hospital, Springfield, ³Boston Children's Hospital, Boston
Background/Purpose: B-cell depletion therapy has increasingly been used for the treatment of childhood-onset rheumatic diseases. Previous studies investigating whether rituximab results in increased infections have…
Abstract Number: 069 • 2020 Pediatric Rheumatology Symposium
Rheumatic Fever in a Tertiary Medical Center – 25 Years of Follow Up
Liora Harel ¹, Gil Amarilyo ² and mohammad hammad saied³, ¹Schneider Hospital, Tel Aviv University, Petah-Tiqva, Israel, ²Schneider Hospital, Tel Aviv University, Kibbutz Magal, Israel, ³Schneider Medical Center, Kaboul village 24963, Israel
Background/Purpose: Rheumatic Fever (RF) occurs after a pharyngeal infection caused by group A-B-hemolytic streptococci.Its principal clinical significance is causing carditis at the acute phase of…
Abstract Number: 138 • 2020 Pediatric Rheumatology Symposium
Serious Infection Risk in Pediatric Patients with Low Immunoglobulin Levels Following Rituximab Treatment for Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
Simone Melega ¹, Paul Brogan², Gavin Cleary ³, Aimee Hersh ⁴, Ozgur Kasapcopur ⁵, Satyapal Rangaraj ⁶, Rae Yeung ⁷, Andrew Zeft ⁸, Jennifer Cooper ⁹, Pooneh Pordeli ¹⁰, Petra Kirchner ¹¹ and Patricia Lehane ¹², ¹F. Hoffmann-La Roche, Ltd., Basel, Switzerland, ²UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ³Alder Hey Children's Hospital, Liverpool, United Kingdom, ⁴University of Utah Primary Children's Hospital, Salt Lake City, ⁵Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Cerrahpasa, Turkey, ⁶Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, ⁷The Hospital for Sick Children, Toronto, Canada, ⁸The Cleveland Clinic - Center for Pediatric Rheumatology & Immunology, Cleveland, Ohio, ⁹University of Colorado, Children's Hospital Colorado, Denver, ¹⁰F. Hoffmann-La Roche, Ltd., Mississauga, Canada, ¹¹F. Hoffmann-La Roche Ltd., Birsfelden, Switzerland, ¹²Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: Low immunoglobulin (Ig) levels can occur after rituximab treatment, but the clinical significance is not completely understood. Not all patients (pts) who develop low…
Abstract Number: 2125 • 2019 ACR/ARP Annual Meeting
Rheumatic Fever in a Tertiary Medical Center – 25 Years of Follow Up
mohammad hammad saied¹, Liora Harel ², Gil Amarilyo ³, rotem tal ⁴ and Razi Zidani ⁵, ¹schneider medical center, kaboul village, Israel, ²Tel Aviv University, Tel Aviv, Israel, ³schneider medical center, petach tekva, ⁴schneider medical center, ramat gan, Israel, ⁵tel aviv university, Tamra, Israel
Background/Purpose: Rheumatic Fever (RF) occurs after a pharyngeal infection caused by group A-B-hemolytic streptococci.Its principal clinical significance is causing carditis at the acute phase of…
Abstract Number: 2521 • 2019 ACR/ARP Annual Meeting
Rituximab Treatment Is Not Associated with Increased Risk of Infection or Mortality in Refractory SLE Patients: Results from the British Isles Lupus Assessment Group Biologics Registry (BILAG-BR)
Stephen McDonald¹, Eoghan McCarthy ², Aysun Aksoy ³, Ben Parker ⁴ and Ian Bruce ⁵, ¹University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom; Manchester University Foundation Trust, The Kellgren Centre, Manchester, United Kingdom, Belfast, Northern Ireland, United Kingdom, ²Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, England, United Kingdom, ³Marmara University Faculty of Medicine, Division of Internal Medicine, Department of Rheumatology, Istanbul, Turkey; University of Manchester, Division of Musculoskeletal and Dermatological Sciences, Manchester, United Kingdom, Istanbul, Istanbul, Turkey, ⁴University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom; Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, United Kingdom, ⁵University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom
Background/Purpose: Mortality in Systemic Lupus Erythematosus (SLE) is increased compared to the general population. We sought to investigate mortality rates and associated factors in a…
Abstract Number: 2583 • 2019 ACR/ARP Annual Meeting
Prevalence and Risk Factors of Herpes Zoster Reactivation in Patients with Biopsy Proven Lupus Nephritis Undergoing Immunosuppressive Therapies
Chi Chiu Mok¹, Kar Li Chan ², Sau Mei Tse ² and Ling Yin Ho ², ¹Department of Medicine, Tuen Mun Hospital, Hong Kong, China (People's Republic), ²Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose: To study the prevalence of Herpes Zoster (HZ) reactivation in patients with biopsy confirmed lupus nephritis (LN) undergoing immunosuppressive therapies.Methods: Patients who had biopsy…
Abstract Number: 2826 • 2019 ACR/ARP Annual Meeting
Risk of Serious Infections in Tofacitinib versus Other Biologic Drug Initiators in Patients with Rheumatoid Arthritis: A Multi-database Cohort Study
Ajinkya Pawar ¹, Rishi Desai ¹, Nileesa Gautam ¹ and Seoyoung C. Kim², ¹Brigham and Women's hospital, Boston, ²Brigham and Women’s Hospital and Harvard Medical School, Boston
Background/Purpose: It is well-known that biologic or targeted synthetic DMARDs increase the risk of serious infections (SIs), but few studies have directly compared the risk…
Abstract Number: 2873 • 2019 ACR/ARP Annual Meeting
Antimicrobial Use Is High in Patients with Rheumatoid Arthritis, and Further Increases with First-Line TNFi Therapy – Nationwide Results from Iceland
Aron H Bjornsson¹, Olafur Palsson ², Mar Kristjansson ³, Petur S Gunnarsson ⁴, Gerdur Grondal ⁵, Bjorn Gudbjornsson ⁶ and Thorvardur J Love ⁷, ¹Department of Medicine, Landspitali, Reykjavík, Iceland, ²Department of Clinical Sciences Lund, Lund University and Skåne University Hospital, Lund, Sweden, ³Department of Infectious Diseases, Landspitali, Reykjavík, Iceland, ⁴Faculty of Pharmaceutical Sciences, University of Iceland and Hospital Pharmacy, Landspitali, Reykjavík, Iceland, ⁵Department of Rheumatology, Landspitali and Centre for Rheumatology Research, Landspitali, Reykjavík, Iceland, ⁶Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ⁷Faculty of Medicine, University of Iceland and Department of Science, Landspitali, Reykjavík, Iceland
Background/Purpose: Severe infections, frequently resulting in hospitalization, are a well-known adverse effects of tumor necrosis factor inhibitors (TNFi). However, studies regarding outpatient treated infections are…
Abstract Number: 848 • 2019 ACR/ARP Annual Meeting
Risk of Serious Infection with Long-Term Use of Low-Dose Glucocorticoids in Patients with Rheumatoid Arthritis
Michael George¹, Joshua Baker ², Kevin Winthrop ³, Qufei Wu ², Lang Chen ⁴, Fenglong Xie ⁵, Huifeng Yun ⁴ and Jeffrey Curtis ⁴, ¹University of Pennsylvania, Philadelphia, ²University of Pennsylvania, Philadelphia, PA, ³Oregon Health and Science University, Portland, OR, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham
Background/Purpose: As many as 30-40% of patients with RA remain on long term glucocorticoids. Infection risk with higher dose glucocorticoids is well known, but evidence…
Abstract Number: 951 • 2019 ACR/ARP Annual Meeting
Avoidable Acute Care Use for Vaccine-Preventable Illnesses Among Medicaid Beneficiaries with Lupus: Demographic and Healthcare Utilization Differences
Candace Feldman¹, Chang Xu ¹ and Karen Costenbader ¹, ¹Brigham and Women's Hospital, Boston, MA
Background/Purpose: Nearly 25% of patients with SLE are hospitalized each year often for outcomes that may have been avoided if patients had received sustained, high…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].